The maker of remdesivir, a drug known to reduce the recovery time of acutely ill coronavirus patients, said Monday it will charge $2,340 for a normal treatment course for people who participate in government health programs in the U.S. and for governments of other developing countries.
Gilead Sciences announced it will charge $390 per vial, with a typical five-day course consisting of six vials.
Patients who have private insurance will be billed $3,120, or $520 a vial.
"We're in [uncharted] territory with pricing a new medicine, a novel medicine, in a pandemic," said Gilead CEO Daniel O'Day.
